Title:
PHARMACEUTICAL USE OF ANTI-TUMOR INHIBIN 2 ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2023/001258
Kind Code:
A1
Abstract:
Provided is the use of a new anti-tumor inhibin 2 (ST2) antibody in the preparation of a drug for preventing or treating inflammatory, allergic or autoimmune diseases. The anti-ST2 antibody can bind to human ST2 with a high affinity, and can block the binding of human ST2 and human IL-33, thereby being capable of effectively inhibiting IL-33/ST2 signaling pathways. The anti-ST2 antibody has the effects of positively preventing and treating inflammatory, allergic or autoimmune diseases.
Inventors:
ZHENG BIN (CN)
MAO YU (CN)
LIANG WENLU (CN)
ZHANG LIN (CN)
MAO YU (CN)
LIANG WENLU (CN)
ZHANG LIN (CN)
Application Number:
PCT/CN2022/107205
Publication Date:
January 26, 2023
Filing Date:
July 21, 2022
Export Citation:
Assignee:
MABWELL SHANGHAI BIOSCIENCE CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P11/06; A61P29/00; A61P37/02; C12N15/13
Domestic Patent References:
| WO2013173761A2 | 2013-11-21 |
Foreign References:
| CN113214395A | 2021-08-06 | |||
| CN110357963A | 2019-10-22 | |||
| CN103845731A | 2014-06-11 | |||
| CN106199002A | 2016-12-07 |
Other References:
KELSEN, S. G. ET AL.: "Astegolimab (Anti-ST2) Efficacy and Safety in Adults with Severe Asthma: A Randomized Clinical Trial", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 148, no. 3, 16 April 2021 (2021-04-16), XP086762505, DOI: 10.1016/j.jaci.2021.03.044
Attorney, Agent or Firm:
LEADING INTELLECTUAL PROPERTY FIRM (CN)
Download PDF: